Advertisement

Treatment of Erythropoietic Porphyrias

  • H. Ippen
Conference paper

Abstract

The following therapeutic approaches are recommended for the main types of hepatic porphyria: (1) for porphyria hepatica chronica, phlebotomies (6) and chloroquine (7), preferably combined, (first, withdrawal of 3–5 1 blood, then twice a week 0.125 g chloroquine until the porphyrin excretion has returned to normal); (2) for acute intermittent porphyria, hematin — as recommended by Watson et al. (1); and (3) for porphyria variegata, the combination of phlebotomies (during remission) (6) and hematin (during the acute attack).

Keywords

Hemolytic Anemia Lead Poisoning Zinc Salt Porphyria Cutanea Tarda Lead Intoxication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bonkowsky, H.L., Tschudy, D.P., Collins, A. et al. : Repression of Overproduction of Porphyrin Precursors in Acute Intermittent Porphyria by Intravenous Infusions of Hematin. Proc. Natl. Acad. Sci. U.S.A. 68, 2725–2729 (1971)PubMedCrossRefGoogle Scholar
  2. 2.
    Goerz, G., Ippen, H.: Aderlassbehandlung der protoporphyrinaemischen Lichtdermatose. Z. Hautkr. 44, 517–519 (1969)Google Scholar
  3. 3.
    Goerz, G., Krieg, T., Bolsen, K.: Porphyria cutanea tarda: Normalisierung der Porphyrin-Ausscheidung unter p-Aminobenzoat (PotabaR). Arch. Dermatol. Res. 255, 331–335 (1976)PubMedCrossRefGoogle Scholar
  4. 4.
    Hönigsmann, H.: Die erythropoetische Protoporphyrie. Z. Hautkr. 52, 495–509,(1977)PubMedGoogle Scholar
  5. 5a.
    Hönigsmann, H.: Die erythropoetische Protoporphyrie. Z. Hautkr.541-564 (1977)Google Scholar
  6. 5b.
    Hönigsmann, H.: Die erythropoetische Protoporphyrie. Z. Hautkr.599-621 (1977)Google Scholar
  7. 6.
    Ippen, H.: Treatment of Porphyria cutanea tarda by Phlebotomy. Semin. Hematol. 14, 253–259 (1977)PubMedGoogle Scholar
  8. 7.
    Kordac, V., Semradova, M.: Treatment of Porphyria cutanea tarda with Chloroquine. Br. J. Dermatol. 90, 95–100 (1974)PubMedCrossRefGoogle Scholar
  9. 8.
    Lamola, A., Piomelli, S., Poh-Fitzpatrick, M. et al. : Erythropoietic Protoporphyria and Lead Intoxication: The Molecular Basis for Difference in Cutaneous Photosensitivity. II. Different Binding of Erythrocyte Protoporphyrin to Hemoglobin. J. Clin. Invest. 56, 1528–1535 (1975)PubMedCrossRefGoogle Scholar
  10. 9.
    Mathews-Roth, M.M., Pathak, M., Fitzpatrick, T.B. et al. : Beta-Carotene as a Photoprotective Agent in Erythropoietic Protoporphyria. N. Engl. Med. 282, 1231–1234 (1970)CrossRefGoogle Scholar
  11. 10.
    Mathews-Roth, M.M., Pathak, M.A., Fitzpatrick, T.B. et al. : ß-Carotene as an Oral Photoprotective Agent in Erythropoietic Protoporphyria. J. Am. Med. Assoc. 228, 1004–1008 (1974)CrossRefGoogle Scholar
  12. 11.
    Moshell, A.N., Bjornson, L.: Photoprotection in Erythropoietic Protoporphyria: Mechanism of photoprotection by Beta-Carotene. J. Invest. Dermatol. 68, 157–160 (1977)PubMedCrossRefGoogle Scholar
  13. 12.
    Piomelli, S., Lamola, A.A., Poh-Fitzpatrick, M.B. et al. : Erythropoietic Protoporphyria and Lead Intoxications: The Molecular Basis for Difference in Cutaneous Photosensitivity. I. Different Rates of Disappearance of Protoporphyrin from the Erythrocytes, both In Vivo and In Vitro. J. Clin. Invest. 56, 1519–1527 (1975)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1978

Authors and Affiliations

  • H. Ippen
    • 1
  1. 1.Dermatologic Clinic of the University of GöttingenGöttingenGermany

Personalised recommendations